Verastem will launch a U.S. phase 1/2a trial of oral KRAS G12D inhibitor VS-7375 after FDA IND clearance, with data to be ...

Gosselies, Belgium Saturday, April 26, 2025, 16:00 Hrs [IST] ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Verastem Oncology (NASDAQ:VSTM) announced on Wednesday that the U.S. FDA has cleared the investigational new drug application ...

Full abstracts will be released by ASCO on Thursday, May 22, 2025, at 5:00 PM ET. Details from the presentations will be available following the event on the Candel website at Candel Media. * Dr.

Statistically significant improvements observed across clinical endpoints; final cohort results expected in Q2 2025 ...

Second Cohort Results Highlight Efficacy Across All Key Measures and Reinforce Safety of Twice-Daily Oral RinsePhase 2a Study Now Fully Enrolled ...

Skye Bioscience currently trades essentially at cash value, meaning investors who buy in today get a weight loss drug ...

Arrowhead Pharmaceuticals, Inc.’s ARWR share price has dipped by 12.32%, which has investors questioning if this is right ...

A phase 2a clinical trial of NEO100-01 is continuing to recruit patients with malignant gliomas, with full enrollment ...